Cortexyme merges with Novosteo

Cortexyme is merging with Novosteo, a biotechnology company that develops drugs to treat rare bone diseases and bone cancer. As a result, Novosteo shareholders will own 15.5% of the merged company, which will be named Quince Therapeutics and will be traded under the ticker symbol QNCX. The merger is expected to be completed within 30 days.